Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study

医学 安慰剂 视神经脊髓炎 内科学 子群分析 危险系数 随机对照试验 随机化 人口 光谱紊乱 物理疗法 儿科 多发性硬化 精神科 置信区间 病理 替代医学 环境卫生
作者
Kazuo Fujihara,Ho Jin Kim,Takahiko Saida,Tatsuro Misu,Yoshito Nagano,Naoko Totsuka,Masahiko Iizuka,Shinsuke Kido,Ryuuji Terata,Kentaro Okumura,Shinya Hirota,Bruce A.C. Cree
出处
期刊:Multiple sclerosis and related disorders [Elsevier]
卷期号:79: 104938-104938
标识
DOI:10.1016/j.msard.2023.104938
摘要

Inebilizumab, an anti-CD19 B cell-depleting antibody, reduced the risk of a neuromyelitis optica spectrum disorder (NMOSD) attack, disability worsening, magnetic resonance imaging (MRI) lesion activity, and disease-related hospitalizations in participants with NMOSD in the N-MOmentum study (NCT02200770). However, the efficacy and safety outcomes of inebilizumab specific to an Asian population were not fully reported. Therefore, subgroup analyses of the N-MOmentum study were conducted post hoc to evaluate the efficacy and safety of inebilizumab in Asian participants with NMOSD.The N-MOmentum study was a multicenter, double-blind, randomized, placebo-controlled phase 2/3 trial with an open-label extension period (OLP). In the subgroup analyses, data from Asian participants from the N-MOmentum study were compared with those of non-Asian participants. Eligible participants were randomly allocated (3:1) to receive 300 mg intravenous (IV) inebilizumab or placebo on Days 1 and 15. Participants who had an NMOSD attack or completed the randomized controlled period (RCP) could enter the OLP, where they received inebilizumab for ≥2 years. All participants who entered the OLP received inebilizumab 300 mg IV every 6 months.Overall, 230 participants received treatment (174 received inebilizumab and 56 received placebo), of whom 47 were Asian (39 received inebilizumab and 8 received placebo). Baseline characteristics were similar between the Asian and non-Asian subgroups, except for disease duration, annualized relapse rate prior to randomization in this study, and previous maintenance therapy. In the Asian subgroup, the risk of NMOSD attacks was reduced with inebilizumab versus placebo (hazard ratio, 0.202) and the attack-free rate at 28 weeks was 82.1% with inebilizumab versus 37.5% with placebo, in the 6-month RCP. NMOSD attack rates were comparable between the Asian and non-Asian subgroups. In the Asian subgroup, the rates of Expanded Disability Status Scale worsening from baseline, active MRI lesions, and disease-related hospitalizations tended to be lower in the inebilizumab group than in the placebo group; similar results were shown in the non-Asian subgroup. For long-term efficacy and safety (RCP and OLP), the annualized adjudicated NMOSD attack rate in Asian participants treated with inebilizumab was reduced (0.096) compared with that at baseline (1.04), with a mean follow-up period of inebilizumab treatment of 3.38 years, which was consistent with the results in the non-Asian subgroup. The risk of NMOSD attack decreased with prolonged duration of treatment in both the inebilizumab/inebilizumab and placebo/inebilizumab groups in the Asian and non-Asian subgroups. The incidence of treatment-emergent adverse events (TEAEs) was similar between the Asian and non-Asian subgroups. In the Asian and non-Asian subgroups, 15.2% and 35.2% of participants, respectively, had at least one serious TEAE and/or Grade ≥3 TEAE during long-term therapy. No deaths occurred in the Asian subgroup whereas three deaths occurred in the non-Asian subgroup.Inebilizumab reduced the risk of an NMOSD attack, progression of disability, MRI lesion activity, and disease-related hospitalizations in Asian participants with NMOSD. The efficacy of inebilizumab in reducing NMOSD attacks continued without any unexpected safety signals or concerns during long-term use in Asian participants.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星空完成签到 ,获得积分10
1秒前
研友_8Y26PL完成签到 ,获得积分10
1秒前
海孩子完成签到,获得积分10
2秒前
Tong应助wangzhihao采纳,获得10
4秒前
菠萝谷波完成签到 ,获得积分10
4秒前
科研顺完成签到 ,获得积分10
5秒前
蓝桉完成签到 ,获得积分10
12秒前
刘天虎研通完成签到 ,获得积分10
13秒前
Dingz完成签到,获得积分10
15秒前
gg完成签到,获得积分10
25秒前
张包子完成签到 ,获得积分10
28秒前
孤独听雨的猫完成签到 ,获得积分10
28秒前
28秒前
陈秋完成签到,获得积分10
34秒前
鬼见愁应助科研通管家采纳,获得10
34秒前
皮卡丘完成签到 ,获得积分10
35秒前
hailiangzheng完成签到,获得积分10
36秒前
陈秋发布了新的文献求助10
37秒前
成就的孤晴完成签到 ,获得积分10
42秒前
Airhug完成签到 ,获得积分10
43秒前
陶冶完成签到,获得积分10
46秒前
FashionBoy应助刘隅采纳,获得10
49秒前
Vegeta完成签到 ,获得积分10
58秒前
SAINT完成签到 ,获得积分10
1分钟前
Patrick完成签到 ,获得积分10
1分钟前
overlood完成签到 ,获得积分10
1分钟前
没头脑和不高兴完成签到 ,获得积分10
1分钟前
Byby完成签到 ,获得积分10
1分钟前
qausyh完成签到,获得积分10
1分钟前
xzn1123应助wodetaiyangLLL采纳,获得10
1分钟前
lixinyue完成签到 ,获得积分10
1分钟前
JamesPei应助研友_LN32Mn采纳,获得10
1分钟前
快乐的幼丝完成签到 ,获得积分10
1分钟前
我独舞完成签到 ,获得积分10
1分钟前
蟲先生完成签到 ,获得积分10
1分钟前
1分钟前
复杂觅山完成签到 ,获得积分10
1分钟前
胜胜糖完成签到 ,获得积分10
1分钟前
幸运草完成签到 ,获得积分10
1分钟前
stiger完成签到,获得积分10
1分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052652
求助须知:如何正确求助?哪些是违规求助? 2709874
关于积分的说明 7418267
捐赠科研通 2354446
什么是DOI,文献DOI怎么找? 1246020
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921